EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy

Mike Wenzel, Cristina C Garcia iD, Benedikt Hoeh, Charlotte Jorias, Clara Humke, Florestan Koll, Nikolaos Tselis, Claus Rödel, Markus Graefen, Derya Tilki iD, Felix K H Chun, Philipp Mandel

The Prostate · 2023

DOI: 10.1002/pros.24599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Transurethral Resection of Prostate. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate characteristics and outcomes of oligometastatic hormone‐sensitive prostate cancer (mHSPC) patients undergoing metastases‐directed therapy (MDT) with external beam radiation therapy (EBRT). Materials and Methods We relied on an institutional tertiary‐care database to identify mHSPC patients who underwent EBRT as MDT between 12/2019 and 12/2022. Main outcomes consisted of progression to metastatic castration‐resistant prostate cancer (mCRPC) and overall mortality (OM). Oligometastatic was defined as ≤3 metastases and bone and/or lymph node deposits were treated with conventional doses up to 54 Gy or with hypofractionated stereotactic regimes of median 24 Gy (20–27 Gy).

Results

Overall, 37 patients treated with EBRT as MDT were identified. The median follow‐up was 13 months. Median age at MDT was 71 years and 84% exhibited ECOG performance status 0. The median baseline PSA at diagnosis was 10 ng/mL. Overall, primary local therapy consisted of radical prostatectomy (65%), followed by external beam radiation therapy to the prostate (11%), focal therapy (8%), and palliative transurethral resection of the prostate (5%). Overall, 32% exhibited de novo oligometastatic mHSPC. Bone metastases were present in 78% versus 19% lymph node metastases versus 3% both. The distribution of targeted oligo‐metastases was 62% versus 38% for respectively one metastasis versus more than one metastasis. Androgen deprivation therapy (ADT) was combined with MDT in 84%. Moreover, 19% received combination therapy with apalutamide/enzalutamide and 12% with abiraterone or docetaxel. The median time to mCRPC was 50 months. In incidence analyses, 13% developed mCRPC after 24 months. OM after 24 months was 15% in mHSPC patients receiving MDT. Significant OM differences were observed after stratification into targeted metastatic burden (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantTransurethral Resection of ProstateMaleHumansAndrogen AntagonistsTreatment OutcomeHormones

Stichwörter der Autor:innen

MDTmHSPColigometastaticsurvival

Substanzen

Androgen AntagonistsHormones

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, Québec, Canada.
  • Department of Radiation and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Koc University Hospital, Istanbul, Turkey.

ORCID-Profile: Cristina C Garcia, Derya Tilki

Zitieren

APA

Wenzel, M., Garcia, C. C., Hoeh, B., Jorias, C., Humke, C., Koll, F., Tselis, N., Rödel, C., Graefen, M., Tilki, D., Chun, F. K. H., & Mandel, P. (2023). Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy. The Prostate. https://doi.org/10.1002/pros.24599

Vancouver

Wenzel M, Garcia CC, Hoeh B, Jorias C, Humke C, Koll F, et al. Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy. The Prostate. 2023. doi:10.1002/pros.24599

BibTeX
@article{Wenzel2023,
  author = {Wenzel, Mike and Garcia, Cristina C and Hoeh, Benedikt and Jorias, Charlotte and Humke, Clara and Koll, Florestan and Tselis, Nikolaos and Rödel, Claus and Graefen, Markus and Tilki, Derya and Chun, Felix K H and Mandel, Philipp},
  title = {Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24599}
}
Kostenlos starten →